Background The pathogenesis and etiology of endometrial polyps has not been elucidated. In this study, we aimed to examine the pathogenic mechanisms of endometrial polyp development using immunohistochemistry. We evaluated the expression of galectin-3 and cyclooxgenase-2 (COX-2) during the menstrual cycle in premenopausal women with endometrial polyps or normal endometrium.
Methods Thirty-one patients with endometrial polyps and 50 healthy control patients were included in this study. The levels of expression of COX-2 and galectin-3 were studied by immunohistochemistry.
Results The percentage of COX-2–positive cells and the intensity of COX-2 staining in the endometrium did not vary during the menstrual cycle either in the control group or in patients with endometrial polyps. However, expression of galectin-3 was significantly lower in endometrial polyps and during the proliferative phase of the endometrium compared with the secretory phase.
Conclusions Our data suggests that the pathogenesis of endometrial polyps does not involve expression of COX-2 or galectin-3.
Citations
Citations to this article as recorded by
Research Progress in the Treatment of Endometrial Polyps 秀芬 蔡 Advances in Clinical Medicine.2024; 14(01): 1772. CrossRef
ER and COX2 expression in endometrial hyperplasia processes Nataliia Tsyndrenko, Mykola Lyndіn, Kateryna Sikora, Andrew Awuah Wireko, Toufik Abdul-Rahman, Nataliia Hyriavenko, Anatolii Romaniuk Medicine.2023; 102(33): e34864. CrossRef
Novel microarchitecture of human endometrial glands: implications in endometrial regeneration and pathologies Nicola Tempest, Christopher J Hill, Alison Maclean, Kathleen Marston, Simon G Powell, Hannan Al-Lamee, Dharani K Hapangama Human Reproduction Update.2022; 28(2): 153. CrossRef
Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer Marcin Oplawski, Konrad Dziobek, Nikola Zmarzły, Beniamin O. Grabarek, Robert Kiełbasiński, Przemysław Kieszkowski, Piotr Januszyk, Karol Talkowski, Michał Schweizer, Piotr Kras, Andrzej Plewka, Dariusz Boroń Current Pharmaceutical Biotechnology.2020; 21(1): 52. CrossRef
Background Parafibromin is a recently defined tumor suppressor gene. The aim of our study was to determine the relationships of parafibromin expression in urothelial carcinomas (UCs) with prognostic parameters and to evaluate the use of parafibromin as a potential marker of UC. Methods: Parafibromin expression was assessed in 49 UC specimens using immunohistochemistry. The correlations between parafibromin expression and clinical and pathologic parameters were investigated. Results: Of the patients, 42 (85.7%) were male, and the mean age was 69.6 ± 8.2 years (range, 54 to 88 years). Morphologically, the UCs were divided into two groups: papillary (n = 27) and non-papillary (n = 22). There were seven low-grade (14.3%) and 42 high-grade (85.7%) tumors. Parafibromin was negative in 13 tumors (26.5%), partially positive in 19 tumors (38.8%), and positive in 17 tumors (34.7%). Parafibromin expression was more negative in UCs from upper urinary locations (n=17) and with muscularis propria invasion (n=28), which was statistically significant (p = .009 and p = .007, respectively). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, survival, or disease-free survival. Conclusions: We found that UC cases with parafibromin positivity had less of a tendency to show muscularis propria invasion and were more commonly located in the lower urinary system. These results need to be confirmed with studies based on larger case series.
Citations
Citations to this article as recorded by
The roles of the tumor suppressor parafibromin in cancer Hua-chuan Zheng, Hang Xue, Cong-yu Zhang Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta‐analysis based on individual patient data Ruizhe Zhu, Zixing Wang, Ya Hu Clinical Endocrinology.2020; 92(4): 295. CrossRef
Thein vitroandin vivoeffects of nuclear and cytosolic parafibromin expression on the aggressive phenotypes of colorectal cancer cells: a search of potential gene therapy target Hua-chuan Zheng, Jia-jie Liu, Jing Li, Ji-cheng Wu, Lei Yang, Gui-feng Zhao, Xin Zhao, Hua-mao Jiang, Ke-qiang Huang, Zhi-jie Li Oncotarget.2017; 8(14): 23603. CrossRef
The clinicopathological and prognostic significances of CDC73 expression in cancers: a bioinformatics analysis Hua-Chuan Zheng, Bao-Cheng Gong, Shuang Zhao Oncotarget.2017; 8(56): 95270. CrossRef
Significance of Parafibromin Expression in Laryngeal Squamous Cell Carcinomas Inju Cho, Mija Lee, Sharon Lim, Ran Hong Journal of Pathology and Translational Medicine.2016; 50(4): 264. CrossRef
Sclerosing Extramedullary Hematopoietic Tumor (SEHT) Mimicking a Malignant Bile Duct Tumor-Case Report and Literature Review Sorin Dema, Fulger Lazar, Robert Barna, Amadeus Dobrescu, Alis Liliana Carmen Dema, Oana Popa, Ioana Ionita, Sorina Maria Taban Medicina.2021; 57(8): 824. CrossRef
Sclerosing Extramedullary Hematopoietic Tumor: A Case Report Dapeng Wang, Eduardo Castro, Arundhati Rao, Christopher Michael McPhaul Journal of Investigative Medicine High Impact Case Reports.2020;[Epub] CrossRef